Last reviewed · How we verify
NCT04303091
The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients
NA trial testing Physical Activity for Advanced Cancer Treatment (PAACT) in Multiple Myeloma in 19 participants. Completed in 20 December 2018.
20 December 2018
Quick facts
| Lead sponsor | Dr. Nicole Culos-Reed |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 19 |
| Start date | 2 March 2018 |
| Primary completion | 20 December 2018 |
| Estimated completion | 20 December 2018 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Physical Activity for Advanced Cancer Treatment (PAACT)
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
- Hematologic Neoplasms — all drugs for Hematologic Neoplasms →
- Advanced Cancer — all drugs for Advanced Cancer →
Sponsor
Dr. Nicole Culos-Reed
Who can join
18 and older, any sex, with Multiple Myeloma or Hematologic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although physical activity (PA) is commonly used to manage symptoms and enhance quality of life (QOL) in cancer survivors, relatively little is known regarding the benefits in advanced multiple myeloma (MM). The primary aims of the Physical Activity in Advanced Cancer Treatment (PAACT) intervention were to examine (1) program feasibility and (2) potential impact on patient outcomes. It is hypothesized that an exercise intervention will be feasible and potentially impactful.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exercise and Diet Studies Among Patients Living with Multiple Myeloma: Current Evidence and Considerations of Patient Preferences.
Maslana KE, Skogerboe GE, Sborov DW, Coletta AM. · · 2025 · PMID 40970124 · DOI 10.3389/frhem.2025.1550681
Verify or expand the search:
- PubMed search for NCT04303091
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04303091 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Nicole Culos-Reed
- Last refreshed: 10 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04303091.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing